News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
Heidelberg Pharma advances to Cohort 9 in Phase I/IIa trial of lead ATAC candidate HDP-101 in multiple myeloma, demonstrating favorable safety profile and early signs of clinical activity -
-
-